Skp2 inversely correlates with p27 and tuberin in transformed cells

被引:3
作者
Rosner, M. [1 ]
Hanneder, M. [1 ]
Siegel, N. [1 ]
Valli, A. [1 ]
Fuchs, C. [1 ]
Hengstschlaeger, M. [1 ]
机构
[1] Med Univ Vienna, A-1090 Vienna, Austria
关键词
Skp2; Tuberin; p27; SCLEROSIS GENE-2 PRODUCT; QUIESCENT CELLS; INHIBITOR P27; HUMAN-DISEASE; S PHASE; P27(KIP1); SURVIVAL; COMPLEX; LOCALIZATION; GROWTH;
D O I
10.1007/s00726-008-0141-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The cyclin-dependent kinase inhibitor p27(Kip1) (p27) is a major gatekeeper of the mammalian cell cycle progression known to be regulated by both, its subcellular localization and its degradation. To allow entrance into S phase and thereby mammalian cell cycle progression p27 must be degraded by a skp2-containing E3 ubiquitin ligase whose task is to target p27 for degradation by the proteasome. The tumor suppressor gene product tuberin directly binds to p27 and protects it from degradation via skp2. Whereas, p27 and tuberin are known to be localized to both, the cytoplasm and the nucleus, the localization of skp2 remained elusive. Here we demonstrate that skp2 is a cytoplasmic and nuclear protein. In addition we found an inverse correlation of the endogenous protein levels of skp2 with p27 and tuberin in different transformed cells and under different growth conditions. These data allow new important insights into this molecular network of cell cycle control.
引用
收藏
页码:257 / 262
页数:6
相关论文
共 36 条
[1]   Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease [J].
Astrinidis, A ;
Henske, EP .
ONCOGENE, 2005, 24 (50) :7475-7481
[2]   p27Kip1 modulates cell migration through the regulation of RhoA activation [J].
Besson, A ;
Gurian-West, M ;
Schmidt, A ;
Hall, A ;
Roberts, JM .
GENES & DEVELOPMENT, 2004, 18 (08) :862-876
[3]   Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype [J].
Besson, Arnaud ;
Hwang, Harry C. ;
Cicero, Samantha ;
Donovan, Stacy L. ;
Gurian-West, Mark ;
Johnson, Dianna ;
Clurman, Bruce E. ;
Dyer, Michael A. ;
Roberts, James M. .
GENES & DEVELOPMENT, 2007, 21 (14) :1731-1746
[4]   p27 as a target for cancer therapeutics [J].
Blain, SW ;
Scher, HI ;
Cordon-Cardo, C ;
Koff, A .
CANCER CELL, 2003, 3 (02) :111-115
[5]   Tuberin, p27 and mTOR in different cells [J].
Burgstaller, S. ;
Rosner, M. ;
Lindengruen, C. ;
Hanneder, M. ;
Siegel, N. ;
Valli, A. ;
Fuchs, C. ;
Hengstschlaeger, M. .
AMINO ACIDS, 2009, 36 (02) :297-302
[6]   SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 [J].
Carrano, AC ;
Eytan, E ;
Hershko, A ;
Pagano, M .
NATURE CELL BIOLOGY, 1999, 1 (04) :193-199
[7]   Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? [J].
Corradetti, M. N. ;
Guan, K-L .
ONCOGENE, 2006, 25 (48) :6347-6360
[8]   The tuberous sclerosis complex [J].
Crino, Peter B. ;
Nathanson, Katherine L. ;
Henske, Elizabeth Petri .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (13) :1345-1356
[9]   Relocalized p27KiP1 tumor suppressor functions as a cytoplasmic metastatic oncogene in melanoma [J].
Denicourt, Catherine ;
Saenz, Cheryl C. ;
Datnow, Brian ;
Cui, Xian-Shu ;
Dowdy, Steven F. .
CANCER RESEARCH, 2007, 67 (19) :9238-9243
[10]   Ras mediates cell survival by regulating tuberin [J].
Freilinger, A. ;
Rosner, M. ;
Hanneder, M. ;
Hengstschlaeger, M. .
ONCOGENE, 2008, 27 (14) :2072-2083